| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8229671 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 7 Pages |
Abstract
One-cycle full-dose docetaxel/cisplatin induction chemotherapy with recombinant human granulocyte colony-stimulating factor followed by pulsed low-dose docetaxel CRT is promising with regard to its antitumor activity, low rates of distant failure, and low toxicity, suggesting that this regimen deserves further investigation.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Yuhchyau M.D., Ph.D., Kishan J. M.D., Ollivier Ph.D., Peter C. Ph.D., Therese B.S., Joy M.D., Raman M.D., Brian M.D., Thomas J. M.D., Richard H. M.D., David W. M.D.,